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Abstract
PURPOSE: This proof of concept study was designed to assess the influence of prescriptionstrength Ibuprofen (IBU) on the repeated bout effect (RBE) of heavy exercise. METHODS: Eight
males (23 ± 4 yrs) with no recent history of lower-body resistance training completed two
separate testing phases separated by a seven-day washout period. Each phase consisted of two
sessions of single-legged resistance exercise (RE), performed on the same leg, separated by ten
days. One RE trial included 10 sets of 10 repetitions of maximal unilateral eccentric leg
extensions at 120% 1RM. Each phase was characterized by a distinct treatment of either 800mg
IBU or placebo (PLA), which subjects consumed 45 minutes prior to RE and in 8h increments for
72h. A randomly counterbalanced, crossover design was utilized so each subject received both
treatments. Muscle recovery variables (soreness, muscle function, plasma creatine kinase) were
measured 24 and 72 hours following each RE session. Magnitude-based inferences were used to
evaluate all outcomes. RESULTS: The increase in ascending and descending muscle soreness
24h after the second session of RE (RE2) was ‘likely’ less with PLA compared to IBU.
Specifically, the reduction in ascending muscle soreness with PLA (RE1: 43mm to RE2: 27mm)
was absent with IBU (RE1: 39mm to RE2: 39mm). A similar response was observed for
descending muscle soreness. Furthermore, the impairment in total work performed 72h after RE2
was ‘likely’ attenuated with PLA (RE1: 598J to RE2: 13.1J), but not IBU (RE1: 335.1J to RE2:
343J). Decreases in work performed in the first five reps followed a similar pattern. Finally, the
impact of IBU on all muscle strength and CK measurements were ‘unclear’. CONCLUSIONS: In
general, IBU consumption appeared to interfere with the RBE, compared to PLA. Follow-up
work is needed to confirm these findings but these preliminary data suggest that prescriptionstrength dosing of IBU following skeletal muscle trauma may need to be reconsidered.

vi
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Chapter 1
Introduction
The earliest documented use of an analgesic substance was willow bark dating
back to approximately 300 B.C. (Hersh, 2000). The value of willow bark was originally
discovered by Hippocrates and used in Europe throughout the Middle Ages to manage
pain associated with childbirth, wounds, ulcers, and inflammation (Hersh, 2000). The
analgesic effect of willow bark had been attributed to Salicylic acid, which was later
isolated and used to create the first non-steroidal anti-inflammatory drug (NSAID),
aspirin. Produced in bulk by Friedrich Bayer and Company, aspirin became available to
the public in 1899 (Hersh, 2000). NSAIDs currently account for approximately 30 billion
annual drug purchases worldwide (Elnachef, 2008) and are primarily used to treat fever,
inflammation, and pain.
NSAIDs deliver their effects by impairing cyclooxygenase (COX) enzyme
activity. NSAIDs prevent COX enzymes from converting arachadonic acid to
prostaglandins (PG). There are two major COX isoforms expressed in human tissue.
COX-1 is found in most tissues and produces PG that control renal function, platelet
aggregation, and gastric mucosa maintenance (Green, 2001; Hata, 2004). Whereas the
COX-2 isoform is expressed in response to cellular damage and produces PG that
regulate inflammatory events. These isoforms are either selectively blocked or
simultaneously blocked (non-selective), depending on the NSAID. For instance, Aspirin
primarily inhibits COX-1, Celebrex primarily inhibits COX-2, and Ibuprofen (IBU) is
non-selective.
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NSAID’s are extensively used among athletes, especially during acute periods of
heavy and/or unaccustomed exercise. Heavy resistance exercise is associated with
inflammation, joint stiffness, muscle soreness, and impaired muscle function. Likewise,
muscle damage biomarkers such as creatine kinase (CK) (Peake, 2005; Willoughby,
2003; Bruunsgaard, 1997; Newham 1986; Paulsen, 2010), Interleukin-6 (IL-6) (Peake,
2005; Willoughby, 2003; MacIntyre, 2001), and myoglobin (Peake, 2005) are also
typically elevated following heavy exercise. Although contemporary research may
suggest otherwise (Peterson, 2003; Donnelly, 1990; Krentz, 2008), NSAID use is
commonly believed to offset these symptoms.
Not only do COX-1 and COX-2 have regulatory roles in the aforestated
physiology, but they also influence processes involved in cellular adaptations to chronic
exercise. Specifically, PGE2 and PGF2a, manufactured by both COX enzymes, are
involved heavily in muscle satellite cell proliferation and differentiation, and protein
turnover (Brewer, 2012). PGF2a stimulates protein synthesis whereas PGE2 stimulates
protein degradation, collectively leading to a faster rate of protein turnover (Rodemann,
1982).

There is good evidence that NSAIDs inhibit satellite cell proliferation

(Mikkelson, 2009; Mackey 2007), protein synthesis (Trappe, 2002; Burd 2010) and PG
synthesis (Markwork, 2014; Trappe, 2001) after acute exercise. Thus, NSAID’s taken
proximal to heavy exercise to reduce inflammation and pain may interfere with recovery
and chronic adaptations. The negative influence of NSAID’s on muscle regeneration and
adaptation has been shown with animal studies (LaPointe, 2002; Soltow, 2006; Shen,
2006). Few similar studies have been performed in humans. Surprisingly, two separate
research groups recently reported that continuous NSAID supplementation either has
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minimal effect or actually amplifies muscle growth in response to chronic resistance
training (Krentz, 2008, Trappe, 2011). The authors speculated that a parallel pathway
may have supercompensated for the COX suppression thereby leading to superior growth
(Trappe, 2011).
Little is known about how NSAID use effects non-hypertrophic adaptations,
particularly with short-term administration that is similar to what is practiced by athletes.
One such adaptation is the repeated bout effect (RBE), where a single session of
‘disruptive’ exercise leads to muscle adaptations that safeguard against similar successive
bouts of exercise-induced muscle damage. Repeated exercise is associated with
progressively less muscle damage and inflammation (Nosaka, 2001; Eston 1996; Byrnes
2004; Paulsen 2010). For example, evidence of reduced muscle damage (lower serum
CK, delayed-onset muscle soreness (DOMS), and myoglobin) has been observed
following a second session of downhill running when a previous downhill run (Byrnes,
1985) or isokinetic exercise had been performed (Paulsen, 2010; Eston, 1996).
Interestingly, these prophylactic adaptations can last up to 6 months in duration (Nosaka,
2001). The mechanisms responsible for prophylactic adaptations remain unclear but
likely include motor unit recruitment strategies, cytoskeletal adaptations and the addition
of sarcomeres (McHugh, 2003). These muscle-specific adaptations likely alter protein
turnover (Trappe, 2001), satellite cell activity (Mackey, 2007), and inflammation
(Lapointe, 2002), all processes that are inhibited by NSAID supplementation. Therefore,
it stands to reason that NSAID supplementation may interfere with muscle remodeling
involved in the repeated bout effect.
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To our knowledge, only one study has examined the influence of NSAIDs on
RBE in humans, and the authors reported null findings (Paulsen, 2010). However,
subjects consumed Celebrex, a selective COX-2 inhibitor that has minimal effect on
COX-1. COX-1 works in conjunction with COX-2 as a partial mediator of exerciseinduced protein synthesis (Burd, 2010). Furthermore, COX-2 is likely responsible for
post-exercise PG production (Trappe, 2011). As a result of its non-selective nature, IBU
has a low-risk profile and seems to have the most impact in the early stages of postexercise recovery on PG synthesis (Markworth, 2014), PGF2a concentrations (Peterson,
2003; Trappe, 2001) and protein synthesis (Trappe, 2002; Peterson, 2003). It is logical to
speculate that IBU may interfere with some of the adaptive characteristics of the RBE,
however this thesis has not been examined. Therefore, the primary aim is to investigate
the effects of IBU supplementation on the RBE elicited by consecutive sessions of
eccentric unilateral knee extensions.
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Aims and Hypotheses
Aim 1: To determine if IBU consumption before and after an initial session of eccentric
resistance exercise influences skeletal muscle function following a second bout of
eccentric resistance exercise, compared to placebo (PLA).
Hypothesis 1: IBU consumption before and after an initial session of eccentric resistance
exercise will result in greater peak torque decrements following a second session of
eccentric resistance exercise, compared to PLA.

Aim 2: To determine if IBU consumption before and after an initial session of eccentric
resistance exercise influences muscle damage (plasma creatine kinase and muscle
soreness) following a second session of eccentric resistance exercise, compared to PLA.
Hypothesis 2: IBU consumption before and after an initial session of eccentric resistance
exercise will result in more muscle damage following a second session of eccentric
resistance exercise, compared to PLA.
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Significance
The prevalence of NSAID use combined with preliminary evidence of impaired muscle
regeneration and protein turnover during post-exercise recovery points to the value of
more research on this topic. Coupling unaccustomed resistance exercise with an antiinflammatory dose of IBU should create an environment conducive for COX enzyme
inhibition of inflammation, satellite cell proliferation and fusion, and protein turnover,
thereby maximizing the potential effect that NSAID’s may have on the RBE. Given the
non-selective nature of IBU, and the partially shared role of both COX-1 and COX-2
isoforms in muscle adaptation, this study will provide insight into the potential for
NSAID treatment to impact skeletal muscle physiology. The findings from this study
may help fitness professionals, recreational exercisers, and athletes make better informed
decisions by weighing short term benefits with possible long term detriments when it
comes to NSAID supplementation.
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Chapter Two
Methods
Subjects
Eight healthy, active males between the ages of 19 and 32 were recruited from
James Madison University. To be included, subjects must not have regularly engaged in
lower body resistance exercise (RE) (> 1 session a week within 3 months of study
participation). Additionally, subjects must not have consumed any form of NSAID within
seven days prior to study participation. Study procedures were approved by the James
Madison University Institutional Review Board. Before participation, and after
comprehensive verbal and written explanations of the study procedures, all subjects
provided written consent. Subject characteristics are presented in Table 1.

Experimental Design
Subjects completed two separate testing phases separated by a washout period of
at least 7 days. Each testing phase consisted of two single-leg RE sessions, performed on
the same leg, separated by ten days (Figure 1). Each phase was characterized by
treatment with either IBU or PLA. A randomly counterbalanced, crossover design was
utilized so that each subject received both treatments. For example, subjects ingesting
IBU for the first session of RE with Leg A ingested a PLA pill, matched for size and
color, for the third session of RE with Leg B, following a 7 day washout period. Prior to
any testing, subjects that met the inclusion criteria completed a VO2max test and four RE
familiarization trials.
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One Repetition Maximum Test (1RM)
Immediately prior to each resistance exercise session, 1RM was tested to
determine the workload used in the unilateral eccentric leg extensions. Subjects warmed
up on a treadmill at a self-selected pace for 5 minutes. They then performed a warm-up of
10 repetitions of unilateral leg extensions at 20% body weight on a standard leg extension
device (Cybex V3 Series, Medway MA, USA). Immediately after, there was 4 minutes of
passive recovery followed by two repetitions at 50%-70% of perceived 1 RM. After an
additional 4 minutes of passive recovery, subjects attempted their 1 RM and continued to
rest in 4-minute segments between attempts until failure.
Resistance Exercise (RE)
The unilateral resistance exercise protocol was adapted from Burd et al.
Following 1RM testing, subjects performed 10 sets of 10 repetitions of unilateral
eccentric leg extensions with a 60 second rest in between sets. The weight was manually
lifted to 180 degrees and lowered to 90 degrees in a 3 second eccentric phase at 120% of
the subject’s concentric 1-repetition maximum. If the weight was lowered in less than 0.5
seconds, the subject completed that set and the following sets were adjusted in 5 pound
increments so they were able to complete the full protocol.

Washout (WO)
A washout (WO) phase of at least 7 days followed the second session of RE for
Leg A. During the WO phase, subjects refrained from any ingestion of NSAIDs, and any
resistance type exercise. Upon completion of the WO phase, subjects participated in
testing phase 2.
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Figure 1. Experimental Design

Non-Steroidal Anti-Inflammatory Drug (NSAID) Treatment
Treatments were administered prior to RE and for 72h following RE. Subjects
received either a PLA pill (lactose) or the anti-inflammatory dose of IBU (2400 mg), split
into 800mg doses, taken three times a day. The first dose was taken approximately 45
minutes prior to the initial bout of resistance exercise and in subsequent 8h time
increments for the next 72 hours. The timing of ingestion immediately after exercise was
recorded and standardized between phases. To verify drug compliance, subjects sent a
text confirming the ingestion of their assigned treatment.

MEASUREMENTS
Cardiorespiratory Fitness (VO2max Test)
Subjects performed a VO2max test to determine maximal oxygen uptake 7 days
prior to the first experimental trial. Subjects rode a computerized cycle ergometer
(Velotron, Racermate Inc, Seattle WA) at a self-selected workload estimated as “a
comfortable, but not easy pace for a 1-hour ride”. Workload was increased by 25 W
every minute until subjects voluntarily requested to stop due to fatigue or are unable to
continue at a cadence >50 rpm. Oxygen uptake was assessed during each stage in 30-s
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intervals using indirect calorimetry via an automated Moxus Modular Metabolic System
(AEI Technologies, Bostrop TX). During the test, heart rate and rate of perceived
exertion (RPE) was also recorded.
Skeletal Muscle Function (SMF)
Peak isokinetic concentric muscle force and work performance was assessed
following a standardized 5-min warm-up on a treadmill. Skeletal muscle function was
assessed six times during each testing phase: Pre-RE 1, RE 1+24h, RE 1+72h, Pre-RE 2,
RE 2+24h, RE 2+72h (Figure 1). Subjects were seated and positioned upright in the
dynamometer chair with knees bent at a 90-degree angle so the axis of the dynamometer
was aligned with the axis of rotation of the knee joint. Adjusting straps were secured
across the subject’s chest, once the chair settings were properly set, to prevent excess
movement associated with each effort. Peak isokinetic concentric torque was assessed by
having subjects push as hard as possible against a shin pad connected to an electronic
dynamometer that controls the speed of movement through the leg-extension. Subjects
performed 2 sets at 30 degrees per second and 2 sets at 120 degrees per second. Each set
consisted of 4 repetitions with the first 2 repetitions acting as a warm-up and the last two
as maximal efforts. Peak isokinetic eccentric torque was assessed by subjects resisting as
hard as possible against the shin pad connected to the electronically controlled
dynamometer. The protocol outlined to test peak isokinetic concentric torque was also
used to test peak isokinetic eccentric torque. All sets were separated by 60 seconds of
rest. Lastly, subjects performed 30 maximum effort leg-extensions at a controlled speed
of movement of 120 degrees per second as an assessment of work performance..
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Muscle Soreness
Soreness ratings were obtained the day of the damaging trial, and 24h and 72h
following each bout of RE. A 100mm visual analog scale, with 0 indicating no muscle
soreness and 100 indicating impaired movement due to muscle soreness was used.
Subjects completed the scale immediately following ascending, and descending a flight
of stairs at normal walking speed.
Venous Blood Draw and Biomarkers
Fasting venous blood samples were obtained from an antecubital vein prior to the
start of each RE trial, 24 hours and 72 hours post RE. Upon entering the lab, subjects
rested in a blood draw chair for 5 minutes prior to receiving the blood draw.
Approximately 10mL of whole blood was obtained at each blood draw, and centrifuged
at 3000 rpm for 20 minutes to remove the plasma portion of the blood. Plasma was stored
in an -80oC freezer for later analysis. Plasma samples were analyzed for muscle
membrane disruption [creatine kinase (CK)]. CK was subsequently analyzed using an
automated table-top analyzer (Chemwell-T, Awareness Tech. Inc., Palm City, FL).

DIETARY AND EXERCISE CONTROLS
Prior to the initiation of testing, subjects were provided with portion sizing guides
and instructed on how to accurately record dietary intake. Subjects maintained a diet
record for 4 days, beginning 24 hours prior to the initial RE trial. Subjects submitted their
initial diet records the morning of their first 72h follow-up trial (from the previous 4
days). Subjects refrained from alcohol and caffeine 24 hour and 12 hours prior to the start
of RE trials and follow-up visits respectively. Subjects consumed their final “self-
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selected” meal no less than 12 hours prior to the start of RE trials and follow-up visits.
Subjects were provided with a standardized meal consisting of a 6-oz yogurt, small box
of cereal, and orange juice following each RE trial. Subjects consumed the meal within
60 minutes of the RE trial completion and abstained from any further food or beverage
intake for the 4 hours following the completion of all RE trials.
Subjects refrained from heavy physical activity 72 hours pre and post RE trial. To
ensure compliance, subjects completed a 72h physical activity log prior to each RE trial.
Subjects did not engage in any heavy exercise in the previous 24h before each RE trial. In
order to avoid any unintended prophylactic adaptions, subjects had not performed any
resistance type of exercise within the previous 3 months.

STATISTICAL ANALYSES
Magnitude-based inferences about the data were derived using methods described
by Hopkins and colleagues (31). A standardized difference in means (mean difference
between treatments divided by the between-subject SD under PLA conditions: SD units)
was calculated for each variable whereby observed values equivalent to or exceeding 0.2
SD units was quantified as a substantial treatment effect (i.e. threshold for substantial
effect) (31). The 0.2 SD unit threshold was used for all variables.
A published spreadsheet (33) was used to determine the likelihoods of the true
treatment effect (of the population) reaching the substantial change threshold (0.2 SD);
these were classified as <1% almost certainly no chance, 1-5% = very unlikely, 5-25% =
unlikely, 25-75% = possible, 75-95% = likely, 95-99% = very likely, and >99% = almost
certain. If the percent chance of the effect reaching the substantial change threshold was
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<25% and the effect was clear, it is classified as a ‘trivial’ effect. If 90% confidence
intervals included values that exceeded the substantial change threshold for both a
positive and negative effect, effects were classified as ‘unclear’ (>5% chance of reaching
the substantial threshold for both a positive and negative effect). For ease of
interpretation data are displayed as raw means ± SD and/or percent difference between
treatments ± CL (90% confidence limit; to illustrate uncertainty in treatment effects).
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Chapter Three
Manuscript
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Abstract
PURPOSE: This proof of concept study was designed to assess the influence of prescriptionstrength Ibuprofen (IBU) on the repeated bout effect (RBE) of heavy exercise. METHODS: Eight
males (23 ± 4 yrs) with no recent history of lower-body resistance training completed two
separate testing phases separated by a seven-day washout period. Each phase consisted of two
sessions of single-legged resistance exercise (RE), performed on the same leg, separated by ten
days. One RE trial included 10 sets of 10 repetitions of maximal unilateral eccentric leg
extensions at 120% 1RM. Each phase was characterized by a distinct treatment of either 800mg
IBU or placebo (PLA), which subjects consumed 45 minutes prior to RE and in 8h increments for
72h. A randomly counterbalanced, crossover design was utilized so each subject received both
treatments. Muscle recovery variables (soreness, muscle function, plasma creatine kinase) were
measured 24 and 72 hours following each RE session. Magnitude-based inferences were used to
evaluate all outcomes. RESULTS: The increase in ascending and descending muscle soreness
24h after the second session of RE (RE2) was ‘likely’ less with PLA compared to IBU.
Specifically, the reduction in ascending muscle soreness with PLA (RE1: 43mm to RE2: 27mm)
was absent with IBU (RE1: 39mm to RE2: 39mm). A similar response was observed for
descending muscle soreness. Furthermore, the impairment in total work performed 72h after RE2
was ‘likely’ attenuated with PLA (RE1: 598J to RE2: 13J), but not IBU (RE1: 335J to RE2: 343J).
Decreases in work performed in the first five reps followed a similar pattern. Finally, the impact
of IBU on all muscle strength and CK measurements were ‘unclear’. CONCLUSIONS: In
general, IBU consumption appeared to interfere with the RBE, compared to PLA. Follow-up
work is needed to confirm these findings but these preliminary data suggest that prescriptionstrength dosing of IBU following skeletal muscle trauma may need to be reconsidered.
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Introduction
NSAIDs (Non-Steroidal Anti-inflammatory Drugs) currently account for
approximately 30 billion annual drug purchases worldwide (Elnachef, 2008) and are
primarily used to treat fever, inflammation, and pain. NSAIDs deliver their effects by
impairing cyclooxygenase (COX) enzyme activity. NSAIDs prevent COX enzymes from
converting arachadonic acid to prostaglandins (PG). There are two major COX isoforms
expressed in human tissue. COX-1 is found in most tissues and produces PG that control
renal function, platelet aggregation, and gastric mucosa maintenance (Green, 2001; Hata,
2004). The COX-2 isoform is expressed in response to cellular damage and produces PG
that regulate inflammatory events. These isoforms are either selectively blocked or
simultaneously blocked (non-selective), depending on the NSAID.
Heavy resistance exercise is associated with inflammation, joint stiffness, muscle
soreness, and impaired muscle function. Likewise, muscle damage biomarkers such as
creatine kinase (CK) (Peake, 2005; Willoughby, 2003; Bruunsgaard, 1997; Newham
1986; Paulsen, 2009), Interleukin-6 (IL-6) (Peake, 2005; Willoughby, 2003; MacIntyre,
2001), and myoglobin (Peake, 2005) are also typically elevated following heavy exercise.
As such, NSAIDs are extensively used among athletes in an attempt to manage acute
periods of heavy and/or unaccustomed exercise.
Not only do COX-1 and COX-2 have regulatory roles in the aforestated
physiology, but they also influence processes involved in cellular adaptations to chronic
exercise. Specifically, PGE2 and PGF2a, manufactured by both COX enzymes, are
involved heavily in muscle satellite cell proliferation and differentiation, and protein
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turnover (Brewer, 2012). Thus, NSAIDs taken proximal to heavy exercise to reduce
inflammation and pain may interfere with recovery and chronic adaptations.
Little is known about how NSAID use effects skeletal muscle adaptations,
particularly with short-term administration. One such adaptation is the repeated bout
effect (RBE), where a single session of ‘disruptive’ exercise leads to muscle adaptations
that safeguard following similar successive bouts of exercise. Repeated exercise is
associated with progressively less muscle damage and inflammation (Nosaka, 2001;
Eston 1996; Byrnes 2004; Paulsen 2010). Interestingly, these prophylactic adaptations
can last up to 6 months in duration (Nosaka, 2001). These muscle-specific adaptations
likely alter protein turnover, satellite cell activity, and inflammation, all processes that are
inhibited by NSAID supplementation.
To our knowledge, only one study has examined the influence of NSAIDs on
RBE in humans, and the authors reported null findings (Paulsen, 2010). However,
subjects consumed Celebrex, a selective COX-2 inhibitor. COX-1 works in conjunction
with COX-2 as a partial mediator of exercise-induced protein synthesis (Burd, 2010).
Furthermore, COX-2 is likely responsible for post-exercise prostaglandin production
(Trappe, 2012). IBU has a low-risk profile and seems to impact several key processes
during the early stages of post-exercise recovery including PG synthesis (Markworth,
2014), PGF2a concentrations (Peterson, 2003; Trappe, 2001) and protein synthesis
(Trappe, 2002; Peterson, 2003). Therefore, the primary aim of this study is to investigate
the effects of IBU supplementation on the RBE elicited by consecutive sessions of
eccentric unilateral knee extensions.
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MATERIALS AND METHOD
Subjects
Eight healthy, active males between the ages of 19 and 32 were recruited from
James Madison University. To be included, subjects must not have regularly engaged in
lower body resistance exercise (RE) (> 1 session a week within 3 months of study
participation). Additionally, subjects must not have consumed any form of NSAID within
seven days prior to study participation. Study procedures were approved by the James
Madison University Institutional Review Board. Before participation, and after
comprehensive verbal and written explanations of the study procedures, all subjects
provided written consent. Subject characteristics are presented in Table 1.

Experimental Design
Subjects completed two separate testing phases separated by a washout period of
at least 7 days. Each testing phase consisted of two single-leg RE sessions, performed on
the same leg, separated by ten days (Figure 1). Each phase was characterized by a distinct
treatment of either IBU or PLA. A randomly counterbalanced, crossover design was
utilized so that each subject received both treatments. For example, subjects ingesting
IBU for the first session of RE with Leg A ingested a PLA pill, matched for size and
color, for the third session of RE with Leg B, following a 7 day washout period. Prior to
any testing, subjects that met the inclusion criteria completed a VO2max test and four RE
familiarization trials.
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One Repetition Maximum Test (1RM)
Immediately prior to each resistance exercise session, 1RM was tested to
determine the workload used in the unilateral eccentric leg extensions. Subjects warmed
up on a treadmill at a self-selected pace for 5 minutes. They then performed a warm-up of
10 repetitions of unilateral leg extensions at 20% body weight on a standard leg extension
device (Cybex V3 Series, Medway MA, USA). Immediately after, there was 4 minutes of
passive recovery followed by two repetitions at 50%-70% of perceived 1 RM. After an
additional 4 minutes of passive recovery, subjects attempted their 1 RM and continued to
rest in 4-minute segments between attempts until failure.
Resistance Exercise (RE)
The unilateral resistance exercise protocol was adapted from Burd et al.
Following 1RM testing, subjects performed 10 sets of 10 repetitions of unilateral
eccentric leg extensions with a 60 second rest in between sets. The weight was manually
lifted to 180 degrees and lowered to 90 degrees in a 3 second eccentric phase at 120% of
the subject’s concentric 1-repetition maximum. If the weight was lowered in less than 0.5
seconds, the subject completed that set and the following sets were adjusted in 5 pound
increments so they were able to complete the full protocol.

Washout (WO)
A washout (WO) phase of at least 7 days followed the second session of RE for
Leg A. During the WO phase, subjects refrained from any ingestion of NSAIDs, and any
resistance type exercise. Upon completion of the WO phase, subjects participated in
testing phase 2.
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Figure 1. Experimental Design

Non-Steroidal Anti-Inflammatory Drug (NSAID) Treatment
Treatments were administered prior to RE and for 72h following RE. Subjects
received either a PLA pill (maltodextrin) or the anti-inflammatory dose of IBU (2400
mg), split into 800mg doses, taken three times a day. The first dose was taken
approximately 45 minutes prior to the initial bout of resistance exercise and in subsequent
8h time increments for the next 72 hours. The timing of ingestion immediately after
exercise was recorded and standardized between phases. To verify drug compliance,
subjects sent a text confirming the ingestion of their assigned treatment.

MEASUREMENTS
Cardiorespiratory Fitness (VO2max Test)
Subjects performed a VO2max test to determine maximal oxygen uptake 7 days
prior to the first experimental trial. Subjects rode a computerized cycle ergometer
(Velotron, Racermate Inc, Seattle WA) at a self-selected workload estimated as “a
comfortable, but not easy pace for a 1-hour ride”. Workload was increased by 25 W
every minute until subjects voluntarily requested to stop due to fatigue or are unable to
continue at a cadence >50 rpm. Oxygen uptake was assessed during each stage in 30-s
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intervals using indirect calorimetry via an automated Moxus Modular Metabolic System
(AEI Technologies, Bostrop TX). During the test, heart rate and rate of perceived
exertion (RPE) was also recorded.
Skeletal Muscle Function (SMF)
Peak isokinetic concentric muscle force and work performance was assessed
following a standardized 5-min warm-up on a treadmill. Skeletal muscle function was
assessed six times during each testing phase: Pre-RE 1, RE 1+24h, RE 1+72h, Pre-RE 2,
RE 2+24h, RE 2+72h (Figure 1). Subjects were seated and positioned upright in the
dynamometer chair with knees bent at a 90-degree angle so the axis of the dynamometer
was aligned with the axis of rotation of the knee joint. Adjusting straps were secured
across the subject’s chest, once the chair settings were properly set, to prevent excess
movement associated with each effort. Peak isokinetic concentric torque was assessed by
having subjects push as hard as possible against a shin pad connected to an electronic
dynamometer that controls the speed of movement through the leg-extension. Subjects
performed 2 sets at 30 degrees per second and 2 sets at 120 degrees per second. Each set
consisted of 4 repetitions with the first 2 repetitions acting as a warm-up and the last two
as maximal efforts. Peak isokinetic eccentric torque was assessed by subjects resisting as
hard as possible against the shin pad connected to the electronically controlled
dynamometer. The protocol outlined to test peak isokinetic concentric torque was also
used to test peak isokinetic eccentric torque. All sets were separated by 60 seconds of
rest. Lastly, subjects performed 30 maximum effort leg-extensions at a controlled speed
of movement of 120 degrees per second as assessment of work performance.
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Muscle Soreness
Soreness ratings were obtained the day of the damaging trial and 24h and 72h
following each bout of RE. A 100mm visual analog scale, with 0 indicating no muscle
soreness and 100 indicating impaired movement due to muscle soreness was used.
Subjects completed the scale immediately following ascending, and descending a flight
of stairs at normal walking speed.

Venous Blood Draw and Biomarkers
Fasting venous blood samples were obtained from an antecubital vein prior to the
start of each RE trial, 24 hours and 72 hours post RE. Upon entering the lab, subjects
rested in a blood draw chair for 5 minutes prior to receiving the blood draw.
Approximately 10mL of whole blood was obtained at each blood draw, and centrifuged
at 3000 rpm for 20 minutes to remove the plasma portion of the blood. Plasma was stored
in an -80oC freezer for later analysis. Plasma samples were analyzed for muscle
membrane disruption [creatine kinase (CK)]. CK was subsequently analyzed using an
automated table-top analyzer (Chemwell-T, Awareness Tech. Inc., Palm City, FL).

DIETARY AND EXERCISE CONTROLS
Prior to the initiation of testing, subjects were provided with portion sizing guides
and instructed on how to accurately record dietary intake. Subjects maintained a diet
record for 4 days, beginning 24 hours prior to the initial RE trial. Subjects submitted their
initial diet records the morning of their first 72h follow-up trial (from the previous 4
days). Subjects refrained from alcohol and caffeine 24 hour and 12 hours prior to the start
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of RE trials and follow-up visits respectively. Subjects consumed their final “selfselected” meal no less than 12 hours prior to the start of RE trials and follow-up visits.
Subjects were provided with a standardized meal consisting of a 6-oz yogurt, small box
of cereal, and orange juice following each RE trial. Subjects consumed the meal within
60 minutes of the RE trial completion and abstained from any further food or beverage
intake for the 4 hours following the completion of all RE trials.
Subjects refrained from heavy physical activity 72 hours pre and post RE trial. To
ensure compliance, subjects completed a 72h physical activity log prior to each RE trial.
Subjects did not engage in any heavy exercise in the previous 24h before each RE trial. In
order to avoid any unintended prophylactic adaptions, subjects had not performed any
resistance type of exercise within the previous 3 months.

STATISTICAL ANALYSES
Magnitude-based inferences about the data were derived using methods described
by Hopkins and colleagues (31). A standardized difference in means (mean difference
between treatments divided by the between-subject SD under PLA conditions: SD units)
was calculated for each variable whereby observed values equivalent to or exceeding 0.2
SD units was quantified as a substantial treatment effect (i.e. threshold for substantial
effect) (31). The 0.2 SD unit threshold was used for all variables.
A published spreadsheet (33) was used to determine the likelihoods of the true
treatment effect (of the population) reaching the substantial change threshold (0.2 SD);
these were classified as <1% almost certainly no chance, 1-5% = very unlikely, 5-25% =
unlikely, 25-75% = possible, 75-95% = likely, 95-99% = very likely, and >99% = almost
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certain. If the percent chance of the effect reaching the substantial change threshold was
<25% and the effect was clear, it is classified as a ‘trivial’ effect. If 90% confidence
intervals included values that exceeded the substantial change threshold for both a
positive and negative effect, effects were classified as ‘unclear’ (>5% chance of reaching
the substantial threshold for both a positive and negative effect). For ease of
interpretation data are displayed as raw means ± SD and/or percent difference between
treatments ± CL (90% confidence limit; to illustrate uncertainty in treatment effects).
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RESULTS
Muscle Soreness
Soreness values following ascension and descension of one flight of stairs 24h
after RE are displayed in Figure 1. Data in parenthesis represents the difference between
the two repeated RE trials for each treatment. RE1 indicates the 1st initial bout of
damaging exercise while RE2 indicates the 2nd subsequent damaging bout of exercise for
one leg.

Ascending stairs
There was a ‘likely’ treatment effect on the RBE for ascending soreness at the 24hr mark. With PLA, the increase in ascending soreness following RE1 (43mm) was ‘very
likely’ greater than the increase in soreness 24 hrs following RE2 (27mm). Conversely,
there were no clear changes in soreness 24 hrs after RE1 (39mm) versus RE2 (39mm)
with IBU.
There were no clear treatment differences in soreness at the 72-hr time point.
Ascending soreness following RE1 (40mm) was ‘likely’ greater than RE2 (15mm) with
PLA. The IBU treatment showed a similar response with soreness ‘likely’ greater after
RE1 (30mm) compared to RE2 (21mm).

Descending stairs
There was a ‘likely’ treatment effect on the RBE for descending soreness at the
24-hr mark. With PLA, the increase in descending soreness following RE1 (55mm) was
‘very likely’ greater than the increase in soreness 24 hrs following RE2 (31mm).
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Conversely, there were no clear changes in soreness 24 hrs after RE1 (48mm) versus RE2
(42mm) with IBU.
There were no clear treatment differences in soreness at the 72-hr time point.
Descending soreness following RE1 (47mm) was ‘very likely’ greater than RE2 (20mm)
with PLA. The IBU treatment showed a similar response with soreness ‘likely’ greater
after RE1 (35mm) compared to RE2 (21mm).

Whole Muscle Function
Peak muscle torque values are displayed in Table 2.

Concentric Isokinetic Peak Torque
There were no clear treatment differences on the RBE at both 24 hrs and 72 hrs
for isokinetic peak torque at 30 deg·sec-1 and 120 deg·sec-1. Decrements in torque at 30
deg·sec-1 24 hrs after RE2 (33 Nm) were ‘possibly’ lower compared to RE1 (49 Nm) with
PLA. However, it was not clear if decreases in torque were less after RE2 (37 Nm)
compared to RE1 (45 Nm) with IBU. Likewise, declines in torque 72 hrs post RE2 (11
Nm) were ‘likely’ smaller in comparison to RE1 (41 Nm) with PLA. Similarly, recovery
after RE2 (23 Nm) compared to RE1 (22 Nm) was not clear with IBU.
It was not clear if decreases in torque at 120 deg·sec-1 24 hrs after RE1 (33 Nm)
were regained after RE2 (30 Nm) with PLA. Contrarily, torque decrements ‘likely’
diminished after RE2 (23 Nm) compared to RE1 (38 Nm) with IBU. Declines in peak
torque 72h following RE1 (34 Nm) were ‘likely’ restored after RE2 (8 Nm) with PLA.
However, it was not clear if decrements in torque recovered after RE2 (12 Nm) compared
to RE1 (17 Nm) with IBU.
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Eccentric Isokinetic Peak Torque
There were no clear treatments effects on the RBE at both 24 hrs and 72 hrs for
isokinetic peak torque at 30 deg·sec-1 and 120 deg·sec-1. Decrements in torque at 30
deg·sec-1 24 hrs following RE1 (44 Nm) were ‘possibly’ lower after RE2 (28 Nm) with
PLA. It was not clear if the same was seen after RE2 (45 Nm) compared to RE1 (62 Nm)
with IBU. Likewise, declines in torque 72 hrs after RE2 (-5 Nm) were ‘likely’ smaller in
comparison to RE1 (25 Nm) with PLA. It was not clear if similar recovery after RE2 (10
Nm) compared to RE1 (17 Nm) was occurred with IBU.
Decreases in torque at 120 deg·sec-1 24 hrs after RE1 (60 Nm) were ‘likely’
regained after RE2 (22 Nm) with PLA. Comparably, torque decrements ‘likely’
diminished after RE2 (38 Nm) compared to RE1 (67 Nm) with IBU. It was not clear if
restoration of peak torque 72 hrs following RE1 (34 Nm) happened after RE2 (-10 Nm)
with PLA. Declines in torque were ‘possibly’ reduced after RE2 (3 Nm) compared to RE1
(17 Nm).

Whole Muscle Performance
Total work values are displayed in Figure 2 and work done in the first 5 reps is
displayed in Figure 3.

Work
There were ‘likely’ treatment effects at both 24 hrs and 72 hrs for total work done
and work performed within the first five reps (FFR). The impairment in total work 24 hrs
following RE2 (365 J) was ‘very likely’ less compared to RE1 (1,005 J) with PLA. With
IBU, the decrement was ‘possibly’ less after RE2 (590 J) as opposed to RE1 (865 J). This
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same pattern was observed at 72 hrs as decreases in work performed ‘likely’ recovered
from RE1 (598 J) to RE2 (13 J) with PLA. It was not clear if differences existed between
RE1 (335 J) and RE2 (343 J) with IBU.
Furthermore, the decrease in FFR 24 hrs following RE1 (307 J) ‘very likely’
improved after RE2 (116 J) with PLA. However, it was not clear if FFR was less impaired
after RE2 (178 J) compared to RE1 (255 J) with IBU. In accordance, the reduction in FFR
72 hrs following RE1 (206 J) ‘likely’ improved following RE2 (9 J) with PLA. There was
no clear improvement from RE1 (84 J) to RE2 (73) with IBU.

Creatine Kinase Levels
CK levels are displayed in Table 3.

Plasma Creatine Kinase (CK)
There were no clear treatment effects on the RBE at both 24 hr and 72 hr time
points. The plasma CK response 24 hr following RE2 (90 U/L) was ‘likely’ diminished
compared to RE1 (144 U/L) with PLA. Similarly, it was ‘likely’ that CK was attenuated
after RE2 (68 U/L) compared to RE1 (145 U/L) with IBU. CK response 72h after RE1
(1590 U/L) was ‘very likely’ larger compared to RE2 (11 U/L) with PLA. However, with
IBU this was not clear as RE1 (686 U/L) was similar to RE2 (-1 U/L).
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DISCUSSION
The primary goal of this proof-of-concept investigation was to determine if shortterm IBU consumption interferes with well-documented skeletal muscle prophylactic
adaptations that occur after an initial bout of heavy unaccustomed exercise, otherwise
known as the RBE. We quantified the magnitude of the RBE by assessing muscle
function and perceived soreness after two identical eccentric exercise sessions (unilateral
leg extension) separated by 10 days. Contralateral legs were exposed to this design, one
with acute IBU and the other with PLA. The main finding was that IBU appeared to
impair the RBE, compared to PLA.
It is well established that after an initial bout of damaging exercise, any
subsequent session of similarly heavy exercise is ensued by comparatively less muscle
soreness (Eston, 1996; Byrnes, 1985) and attenuated impairments in muscle function
(Eston, 1996). A RBE clearly occurred in the present study at both 24 hrs and 72 hrs
following damaging exercise in virtually all of the markers during the PLA treatment
(soreness, 30 deg/sec concentric and eccentric peak torque at 72h, 120 deg/sec concentric
peak torque at 72h, 120 deg/sec eccentric peak torque at 24h, total work, work performed
in the first 5 reps and CK). Evidence of a RBE with IBU was less consistent (soreness at
72h, 120 deg/sec concentric and eccentric peak torque at 24h, and CK at 24h). These
separate adaptations lead to clear treatment differences in the RBE between IBU and
PLA, altogether suggesting that IBU inhibits prophylactic adaptations. There is only one
similar study available for comparison and it contradicts the current data (Paulsen, 2010).
However, Paulsen used a smaller drug dose (400mg) and a different class of NSAID
(Celebrex – COX-2 Inhibitor). We administered IBU to target both COX-1 and COX-2
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pathways, as COX-1 is thought to be involved in cellular pathways necessary for skeletal
muscle remodeling such as protein synthesis and satellite cell proliferation. Specifically,
COX-1 is believed to be involved in the increase in protein synthesis following exercise
(Burd, 2010) and PG production necessary for early signaling post-exercise recovery
(Markworth, 2014). Indeed, IBU has been shown to suppress protein synthesis (Trappe,
2002) and PGF2a production (Trappe 2001) following exercise, while COX-2 inhibition
has not (Burd, 2010). Similarly, satellite cell proliferation has also occurred through the
use of nonselective COX inhibitors similar to IBU (Mackey, 2007; Mikkelson, 2010) but
not with COX-2 inhibitors (Paulsen, 2010).

Another possible explanation for the

discrepant findings is that Paulson administered 400mg of Celebrex twice a day
compared to the 800 mg IBU dose taken thrice a day in the present study. The dosage
used by Paulsen is not considered anti-inflammatory (Abramson, 1989) and may not be a
large enough stimulus to cause any disruption in muscle regeneration and function.
In humans, long-term effects of using non-selective COX inhibitors, Naproxen
sodium and IBU, have been documented (Krentz, 2008; Brewer, 2015). Although NSAID
supplementation had negative effects on early adaptations to resistance exercise in the
more recent study, these impacts diminished over the course of the 6-week resistance
training program and had no repercussions on morphological adaptations (Brewer, 2015).
Comparably, IBU did not influence muscle hypertrophy or strength following 6 weeks of
resistance training in the earlier investigation (Krentz, 2008). Though it is difficult to
extrapolate the current data, it is possible that the negative impact of IBU on the RBE in
the first 10 days observed here may dissipate over time. Though the differences in
exercise stimulus and amount of IBU taken may affect skeletal muscle remodeling for an
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extended duration. In rebuttal, one animal study communicates how non-selective COX
inhibition may have negative long-term consequences on skeletal muscle. Concerning
findings were revealed when rabbits were administered Flurbiprofen (non-selective COX
inhibitor) (Mishra, 2006). Those treated with the NSAID enhanced muscle function more
so than the controls at days 3 and 7 after one damaging bout of exercise. However, 28
days later torque deficits increased and force production decreased in the Flurbiprofen
group (Mishra, 2006). It is worthy to note that while this study did not examine the RBE,
the associated long-term impairment hints at the possible consequences of using nonsteroidal anti-inflammatory drugs.
The current research design also allowed us to provide insight into the
prophylactic efficacy of IBU following acute exercise. The aforementioned dosage of
2400mg of IBU has only been used one other time to our knowledge (Pizza, 1998).
Findings indicated prophylactic IBU consumption did not influence peak torque and
isometric strength after performing one bout of eccentric arm curls (Pizza, 1998).
Conversely, NSAID use has assisted with an increase in muscle function acutely after
heavy exercise (Hasson, 1993; Mishra, 2006). This was not the case within the present
study as it was ‘unclear’ if muscle soreness, CK, peak torque and work performed
benefited from IBU consumption after the initial bout. These findings are in agreement
that IBU consumption does not influence muscle soreness (Bourgeois, 1999; Krentz,
2008; Trappe, 2001) or muscle damage (Bourgeois, 1999).
The subjects in the current study had a wide range of body masses; 69 to 105 kg,
potentially adding variability to the outcomes. Although it has yet to be thoroughly
examined, it is possible that 2400mg of IBU administered to individuals of a larger body
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mass may not elicit the same response as subjects with less body mass. However, a
previous investigation with individuals of similar mass to the current study found that
1200mg of IBU elevated serum IBU concentrations and attenuated PG synthesis to a
similar extent across subjects (Markworth, 2014). Therefore, the current dose was likely
enough to suppress inflammatory processes in all subjects. Furthermore, the correlation
between body mass and the affect of IBU on the RBE was 0.045, suggesting that body
mass had virtually no influence on the results.
In general, the data indicate that IBU consumption blunted the RBE. This was
most obvious for muscle soreness and leg extension work. To our knowledge, this is the
first evidence that acute IBU consumption proximal to initial damaging exercise hinders
tolerance to the subsequent bout of heavy exercise. We recommend thoughtful
consideration before consuming IBU as a recovery aid, as it may negatively influence
adaptations necessary to protect the muscle from subsequent bouts of damaging exercise.
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Table 1. Descriptive Characteristics
Height (cm)
N=8
179.6 ± 7.0
Data are displayed as mean ± SD.

Mass (kg)
82.1 ± 12.3

Age (yrs)
22.8 ± 4.1

VO2max (ml/kg/min)
45.3 ± 7.0
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Table 2. Raw peak isokinetic torque values (Nm)
Variable

Treatment

Speed
(deg·sec-1).

RE1

RE2

Pre

24h

72h

Pre

24h

72h

30

221.0
± 57.9

175.6
± 62.7

199.3
± 63.9

223.1
± 58.3

186.0
± 61.2

199.6
± 52.5

120

197.3
± 32.2

159.7
± 35.2

180.8
± 43.2

195.8
± 29.1

172.9 *
± 33.5

184.1
± 33.2

30

218.0
± 67.7

169.3
± 56.7

176.8
± 78.7

215.5
± 59.9

183.0 *
± 48.8

205
± 49.6

120

199.6
± 34.4

167.1
± 33.2

165.2
± 52.1

192.2
± 29.5

162.3
± 24.0

184.3*
± 23.3

30

278.7
± 81.6

216.5
± 71.3

261.8
± 83.8

270.5
± 87.0

226.0
± 70.7

260.9
± 88.6

120

289.0
± 65.5

221.9
± 78.1

271.8
± 85.1

271.2
± 63.9

233.0 *
± 72.4

267.9
± 72.4

30

247.3
± 58.7

203.8
± 64.2

222.2
± 70.7

250.6
± 69.3

222.8
± 78.0

255.9*
± 79.5

120

270.8
± 52.0

210.6
± 55.9

237.3
± 82.8

260.8
± 77.0

239.3 *
± 63.9

270.4
± 69.8

IBU
Concentric
PLA

IBU
Eccentric
PLA
Data are displayed as mean ± SD * RBE ‘likely’
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Table 3. CK values (U/L) Pre, 24h and 72h post RE.
Treatment
IBU

PLA

Pre

24h

72h

RE1

114.8 ± 31.2

259.3 ± 147.8

800.7 ± 1360.3

RE2

124.7 ± 35.4

192.6 ± *59.10

118.5 ± 28.5

RE1

127.4 ± 66.8

RE2

143.0 ± 46.6

271.8 ± 111.7
233.3 ± *84.00

1515.8 ± 1992.1
143.5 ±*56.4

Data are displayed as mean ± SD *RBE ‘likely’
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Figure 1. Experimental Design
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Figure 2. Difference in perceived ascending muscle soreness from pre to 24 hrs and
pre to 72h following RE.
60

Muscle Soreness (mm)

50

40
+
*

Pre-24h

30
*

Pre-72h
*

20

10

0
IBU [RE1]

IBU [RE2]

PLA [RE1]

PLA [RE2]

[RE2] values represent muscle soreness assessed 10 days after the first IBU
or PLA trial [RE1]. Data are displayed as mean ± SE.
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Figure 3. Difference in total work performed from pre to 24h and pre to 72h.
IBU [RE1]

IBU [RE2]

PLA [RE1]

PLA [RE2]

0
-200

*
+

Total Work (J)

-400

-600

*

Pre-24h
Pre-72h

-800

-1000
-1200
-1400
[RE2] values represent work performed 10 days after the first IBU or
PLA trial [RE1]. Data are displayed as mean ± SE. *RBE ‘likely’
+ Difference in treatment ‘likely’
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Figure 4. Difference in work performed during the first five reps from pre to 24h and
to 72h.
IBU [RE1]

IBU [RE2]

PLA [RE1]

PLA [RE2]

0

-50

Work (J)

-100

-150

-200

*
+

pre-24
*
+

-250

-300

-350
[RE2] values represent work performed 10 days after the first IBU or PLA
trial [RE1]. Data are means ± SE.
*RBE ‘likely’
+ Difference in treatment ‘likely’

pre-72
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Appendix A
Maximum VO2 Data Table
Bike
Date_______________
Subject__________
Age___________
Height (cm)___________
Seat Height:_____________
Seat Fore/aft:_____________

Gender__________
Body Weight (kg)________
Resting HR_____________
Handlebar Height:___________
Handlebar fore/aft:___________

Have subject rest for 5 minutes for resting HR
Nosepiece
Subject will determine starting workload; Increase workload 25 W every 1 min
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Appendix B
PAIN Study
Familiarization Trial
Subject #: _________

Date:_____________

Trial:

FAM2

FAM1

Leg Involved:

Left

Explain the protocol in detail to ensure the subject knows what is expected.
5 minute warm up on treadmill at 3.0 mph
BIODEX
Chair position:_______
Seatback position:________
Machine position:________
Seat height:_________
Arm attachment position:_________

Speed

Concentric PeakT

Eccentric PeakT

30

__________

__________

30

__________

__________

120

__________

__________

120

__________

__________

Fatigability
Work 1st third

Work Last third

____________

____________

Fatigue Index:__________

Right
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Appendix C
Muscle Soreness Questionnaire
Subject #

Date:

Trial:

A

B

C

Circle:

Pre

24h

72h

Leg Involved:

Right

D

Left

Muscle Soreness
Please place a mark on the line below corresponding to your level of muscle soreness
0 millimeters (left) = complete absence of muscular soreness
100 millimeters (right) = extremely sore with noticeable pain and stiffness at all times

Pressure while seated:

0 mm

100 mm

Ascending 1 flight of stairs:
0 mm

100 mm

Descending 1 flight:
0 mm

Notes:

100 m
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Appendix D
PAIN Study
Experimental Trial
Subject #: _________

Date:___________

Trial: A

B

C

Circle: Pre

24h

72h

D
Leg Involved:

Left

Right

Explain the protocol in detail to ensure the subject knows what is expected.
5 minute warm up on treadmill at 3.0 mph
BIODEX
Chair position:_______
Seatback position:________
Machine position:________
Seat height:_________
Arm attachment position:_________
Speed

Concentric PeakT

Eccentric PeakT

30

__________

__________

30

__________

__________

120

__________

__________

120

__________

__________
Fatigability

Work 1st third

Work Last third

____________

____________

Fatigue Index: _______________
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Appendix E
PAIN Study
Experimental Trial
Subject Number:____
Trial: A

B

C

Date:____________
D

1 repetition maximum protocol:
10 warm up reps at 20% body weight
4 minutes of passive recovery
2 reps at 50-70% of their perceived 1RM
4 min of passive recovery
1RM attempt
4 min of passive recovery
Repeat until failure

20% body weight:_______lbs.
50-70% perceived 1RM:_______lbs.
First 1RM attempt:_______lbs.
Second 1RM attempt:_______lbs.
Third 1RM attempt:_______lbs.
Fourth 1RM attempt:________lbs.
Fifth 1RM attempt:________lbs.
Sixth 1RM attempt:________lbs.
1RM:______lbs.
120% of 1RM:________lbs.

Damaging protocol:
10 sets of 10 repetitions at 120% 1RM
1. Set # when weight was lowered:_____
Weight lowered to:_______lbs.
2. Set # when weight was lowered:_____
Weight lowered to:_______lbs.
3. Set # when weight was lowered:_____
Weight lowered to:_______lbs.
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Appendix F
James Madison University
Human Research Review Request
FOR IRB USE ONLY:
Exempt:

Protocol Number:

1st Review:

Expedite
d:
Full
Board:

IRB: 15-0445

2nd Review: X

Project Title:
Project
Dates:
(Not to
exceed 1 year
minus 1 day)

Minimum #
of
Participants:
Maximum #
of
Participants:
External
Funding:

Reviewer:
Reviewer:

rd

Received: 02/16/15 3 Review:

Does Ibuprofen Interfere With Prophylactic Adaptations to Heavy
Exercise?
From: 2/15/15 To: 2/14/16
MM/DD/YY MM/DD/YY

8

12

Yes:
No:
If yes, Sponsor:

Internal
Funding:

Yes:

Will monetary incentives be offered with funding? Yes:

No:

No:

If yes: How much per recipient? Three drawings for $125 each In
what form? Check
Must follow
JMU
Financial
Policy:

http://www.jmu.edu/financemanual/procedures/4205.shtml#.391Incenti
ves
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Responsible
Researcher(s)
:

Nicholas D. Luden, Ph.D.
Jessica G. Ehrbar

E-mail
Address:

ludennd@jmu.edu
ehrbarjg@jmu.edu

Telephone:
Department:
Address
(MSC):

Please Select:
(if Applicable):

540-568-4069
Kinesiology
2302
Faculty

Undergraduate Student

Administrator/Staff Member

Graduate Student

Research
Advisor:
E-mail
Address:
Telephone:
Department:
Address
(MSC):
Investigator: Please respond to the questions below. The IRB will utilize your
responses to evaluate your protocol submission.
1.

NO Does the James Madison University Institutional Review Board define
the project as research?
The James Madison University IRB defines "research" as a "systematic investigation
designed to develop or contribute to generalizable knowledge.” All research
involving human participants conducted by James Madison University faculty and
staff and students is subject to IRB review.

2.

YES NO Are the human participants in your study living individuals?
“Individuals whose physiologic or behavioral characteristics and responses are the
object of study in a research project. Under the federal regulations, human subjects
are defined as: living individual(s) about whom an investigator conducting research
obtains:
(1) data through intervention or interaction with the individual; or (2) identifiable
private information.”

3.

YES

YES

NO Will you obtain data through intervention or interaction with these
individuals?
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“Intervention” includes both physical procedures by which data are gathered (e.g.,
measurement of heart rate or venipuncture) and manipulations of the participant or the
participant's environment that are performed for research purposes. “Interaction”
includes communication or interpersonal contact between the investigator and
participant (e.g., surveying or interviewing).
4.

5.

YES

NO Will you obtain identifiable private information about these
individuals?
"Private information" includes information about behavior that occurs in a context in
which an individual can reasonably expect that no observation or recording is taking
place, or information provided for specific purposes which the individual can
reasonably expect will not be made public (e.g., a medical record or student record).
"Identifiable" means that the identity of the participant may be ascertained by the
investigator or associated with the information (e.g., by name, code number, pattern of
answers, etc.).
YES

NO Does the study present more than minimal risk to the
participants?
"Minimal risk" means that the risks of harm or discomfort anticipated in the proposed
research are not greater, considering probability and magnitude, than those ordinarily
encountered in daily life or during performance of routine physical or psychological
examinations or tests. Note that the concept of risk goes beyond physical risk and
includes psychological, emotional, or behavioral risk as well as risks to employability,
economic well being, social standing, and risks of civil and criminal liability.

CERTIFICATIONS:
For James Madison University to obtain a Federal Wide Assurance (FWA) with the Office
of Human Research Protection (OHRP), U.S. Department of Health & Human Services, all
research staff working with human participants must sign this form and receive training in
ethical guidelines and regulations. "Research staff" is defined as persons who have direct
and substantive involvement in proposing, performing, reviewing, or reporting research and
includes students fulfilling these roles as well as their faculty advisors. The Office of
Research Integrity maintains a roster of all researchers who have completed training within
the past three years.
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Test module at ORI website
http://www.jmu.edu/resandearchintegrity/irb/irbtraining.shtml
Training Completion Date
Name of Researcher(s) and Research
Advisor
Nicholas D. Luden
Jessica G. Ehrbar
Dr. Kent Diduch, M.D.

For additional training interests, or to access a Spanish version, visit the National
Institutes of Health Protecting Human Research Participants (PHRP) Course at:
http://phrp.nihtraining.com/users/login.php.
By signing below, the Responsible Researcher(s), and the Faculty Advisor (if
applicable), certifies that he/she is familiar with the ethical guidelines and regulations
regarding the protection of human research participants from research risks. In
addition, he/she agrees to abide by all sponsor and university policies and procedures
in conducting the research. He/she further certifies that he/she has completed
training regarding human participant research ethics within the last three years.
_________________________________________ ________________
Principal Investigator Signature
Date
_________________________________________ ________________
Principal Investigator Signature
Date
______________________________ ________________
Principal Investigator Signature

Date

_________________________________________ ________________
Faculty Advisor Signature

Date

Submit an electronic version (in a Word document) of your ENTIRE protocol to
researchintegrity@jmu.edu.
Provide a SIGNED hard copy of the Research Review Request Form to:
Office of Research Integrity, MSC 5738, 601 University Boulevard, Blue Ridge Hall, Third
Floor, Room # 342
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Purpose and Objectives
Rationale
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used after performing
unaccustomed exercise, presumably in an attempt to manage the resulting inflammation
and soreness/stiffness. Mechanistically, NSAIDs elicit their effect by interfering with the
COX enzyme (COX-1 and/or COX-2) pathway to prevent the conversion of arachadonic
acid to prostaglandins (3). While COX inhibition may transiently mask the acute
detrimental consequences of heavy exercise (soreness and inflammation) (4,7),
manipulation of this pathway also influences cellular processes needed for desirable
adaptations to repeated exercise. Specifically, various NSAIDs (both COX-2 and COX1/COX-2 inhibitors) can blunt post-exercise protein synthesis and satellite cell
proliferation (5,9). Therefore, it is logical to speculate that NSAID supplementation may
interfere with select cellular adaptations to heavy exercise.
The prophylactic effect of exercise is a hallmark adaptation that commences following
the first session of naïve exercise so that subsequent bouts of identical exercise elicit
progressively less damage and functional impairment. While one recent study reported
that short-term COX-2 inhibition (Celebrex) does not interfere with prophylactic
adaptations (7), there is good reason to believe that simultaneous COX-1 and COX-2
inhibition (Ibuprofen) is more potent and therefore may be more likely to negatively
impact prophylactic adaptations. Moreover, previous research on the topic used the
largest over the counter dose of Ibuprofen (1200 mg/day) despite the fact that it is well
known that prescription strength Ibuprofen doses (2400 mg/day) not only relieves pain
but also influences inflammation, which has an important role in tissue remodeling. Thus,
the aim of the proposed study is to test the hypothesis that acute prescription strength
Ibuprofen treatment will impair prophylactic adaptations, thereby leading to greater
muscle damage and impaired recovery following a subsequent session of heavy
resistance exercise (following drug washout), compared to a placebo treatment.
Note: All potential subjects will be seen by Dr. Diduch at the James Madison University
student health center where they will complete the health history questionnaire, screening
questionnaire (attachments B & E) and be health screened. Low risk subjects (described
below) will receive a prescription for placebo (800 mg 3 x day for 72 hours – 9 doses),
and Ibuprofen (800 mg 3 x day for 72 hours) to be filled at the James Madison University
student health center pharmacy. JMU pharmacist Ron French has agreed to prepare
bottles of placebo and Ibuprofen and to dispense the bottles to our research subjects.
Copies of screening materials will be kept on file at the health center and copies will be
obtained for our records at the Human Performance Laboratory.
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Significance
These findings may be used to help fitness professionals, recreational exercisers, and
athletes make better-informed decisions regarding NSAID supplementation, as they
weigh short-term benefits against possible long-term consequences.
Procedures
Source and Number of Subjects
8-12 recreationally active male adults will be recruited from James Madison University
and the surrounding area. The researchers will discuss the study with
undergraduate/graduate students in Kinesiology, University Sports clubs, and will also
recruit using word of mouth and social media (i.e. facebook). Information provided to
potential subjects will include: basic criteria for inclusion in the study, a brief description
of the study demands, and benefits of participation (see Attachment A). Subjects will be
selected using the inclusion criteria below, based on their responses to questionnaires
(Attachments B, E). Note that female subjects will not be included. We have a track
record of incorporating females when feasible. However, it is well known that estrogen
levels, and therefore menstrual phase, impact muscle recovery, the chief variable in this
study. So, the cost of additional analyses and design requirements of this particular
project prevent us from including females.
Inclusion Criteria
To be eligible for study participation, each subject must meet the following criteria:






Age and Sex: Males: 18-45 years
Subjects must not have performed resistance exercise (RE) or been a part of a
resistance training program within the last 3 months.
NSAID use: Subjects will not have consumed NSAID’s within the previous 7
days.
Subjects are willing and able to give written informed consent, and to understand,
participate and comply with the study requirements
Health: Characterized as “low risk” for exercise complications using criteria from
the American College of Sports Medicine’s Guidelines for Exercise Testing and
Prescription (9th Ed., ACSM, 2014). Low risk is characterized by the ACSM as
individuals “who are asymptomatic and register no more than one risk factor
threshold” from the list below:
- Age: Males > 45 yrs
- Family History: Myocardial infarction, coronary revascularization, or
sudden death before 55 years of age in father or other male first-degree
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-

-

-

-

relative, or before 65 years of age in mother or other female first-degree
relative.
Cigarette Smoking: Current cigarette smoker or those who quit within the
previous 6 months.
Hypertension: Systolic blood pressure ≥ 140 mmHg or diastolic ≥ 90
mmHg, confirmed by measurements on at least two separate occasions, or
on antihypertensive medication.
Dyslipidemia: Low-density lipoprotein (LDL) cholesterol > 130 mg/dl or
high-density lipoprotein (HDL) < 40 mg/dl, or on lipid-lowering
medication. If total serum cholesterol is all that is available use > 200
mg/dl rather than LDL ≥ 130 mg/dl.
Impaired fasting glucose: Fasting glucose ≥ 100 mg/dl confirmed by
measurements on at least two separate occasions
Obesity: Body mass index > 30 kg/m2
Sedentary lifestyle: Persons not participating in a regular exercise program
or not meeting the minimal physical activity recommendations from the
U.S. Surgeon General’s Report
High-serum HDL Cholesterol: This is considered a “negative risk factor”,
so 1 of the above risk factors can be subtracted if HDL > 60 mg/dl

As recommended by the ACSM, we will use the AHA/ACSM Health/Fitness
Facility Pre-participation Screening Questionnaire to identify the above criteria
above (ACSM, 2014, p. 25; see Attachment B).
Study Design
General Description
The intent of this design is to determine whether short-term Ibuprofen use during a
critical window of recovery (72 hours) influences longer-term prophylactic adaptations.
The proposed project will implement a randomized, double blind, placebo-controlled,
crossover design whereby subjects will perform unilateral leg-extension resistance
exercise. For each subject, one leg will be assigned to Placebo whereas the contralateral
leg will be assigned Ibuprofen (treatments will be administered for 3 days following the
initial session of unaccustomed exercise). For example, approximately 7 days following
preliminary testing, 6 subjects will perform one-legged resistance exercise and receive
Placebo capsules whereas 6 subjects will perform one-legged resistance exercise and
receive Ibuprofen (Leg A – Exercise Session 1). The same leg will undergo identical
exercise 10 days later, without treatment (Leg A – Exercise Session 2). Recovery will be
assessed following each session. 10 days following the Leg A – Exercise Session 2, the
opposite leg will perform one-legged resistance exercise and receive the opposite
treatment (Leg B – Session 1). Leg B will then perform identical exercise 10 days later,
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again without treatment (Leg B – Exercise Session 2). A schematic of the general study
design is displayed in Figure 1.
Subjects will receive the treatment in intermittent doses for 72 hours with treatments
commencing on the morning of the first resistance exercise trial. The same leg will be
tested again 10 days later allowing for full muscle recovery, for blood markers to return
to baseline, and for Ibuprofen to ‘wash-out’ so that it does not affect muscle recovery
following the second session of knee extensions. This will allow us to profile the
prophylactic effect without the confounding acute impact of Ibuprofen.

Figure 1: Study Design

Leg A

Leg B

Leg A

Leg B

RE= resistance exercise; Recovery will be assessed at 24 and 72 hrs following each
RE.
The study will consist of a total of sixteen (16) laboratory visits totaling approximately 11
hours of commitment (in addition to completing dietary records). Specifically, subjects
will report to the laboratory for one pre-testing trial, three familiarization trials, four
resistance exercise trials, and eight follow-up trials. Detailed information for each of
these trials is provided below:
Pre-testing 1 (60 min):


Informed Consent – Before testing is initiated, subjects will be given consent
forms to read and sign that provide a comprehensive description of the study, the
risks and benefits associated with the study, and the ways in which confidentiality
will be maintained (see Informed Consent).
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Body Mass and Height - Subjects will have their body weight measured to the
nearest 0.2 kg, and height measured to the nearest 0.5 cm.



VO2max - During this assessment, subjects will perform a graded exercise test to
determine their maximal oxygen uptake (VO2max). Subjects will ride a cycle
ergometer at a self-selected workload estimated as “a comfortable, but not easy
pace for a 1-hour ride”. Workload will be increased by 25 W every 2 minutes
until subjects voluntarily request to stop due to fatigue or are unable to continue at
a cadence >50 rpm. Oxygen uptake will be assessed at each stage during this test.
VO2max will be assessed directly from data obtained during the test and used as a
descriptive characteristic.



Skeletal Muscle Function Familiarization – Peak isokinetic concentric muscle
force and muscle fatigability will be assessed following the VO2max. This test will
be conducted using a Biodex muscle function device (Biodex Medical Systems
Inc., Shirley NY). Muscle function will be assessed by having subjects push as
hard as possible against a shin pad that is connected to an electronic device that
controls speed of movement through the leg-extension. 10 continuous legextension repetitions will be performed. Note: Only 10 repetitions will be
performed to minimize muscle adaptation to practice. Actual testing will include
30 repetitions. The purpose of this session is to familiarize the subjects with the
equipment and procedures to minimize learning and improve reliability during the
experimental trials.

Familiarization Trials (n =3; 15 minutes each):


Skeletal Muscle Function - Peak isokinetic concentric muscle force and
fatigability will be assessed following a standardized treadmill warm-up (3.5
mph; 5 min). See above for details. When combined with the initial skeletal
muscle function familiarization test described above, each leg will receive two
familiarization trials.

Resistance Exercise Trials (n=4; 60 minutes each):


Muscle Soreness - Soreness ratings will be obtained using a 100mm visual analog
scale, with 0 indicating no muscle soreness and 100 indicating impaired
movement due to muscle soreness. Subjects will also be asked to complete the
scale immediately following ascending, and descending a flight of stairs at normal
walking speed.



Blood Sample – Following 5 min of seated rest, fasting venous blood samples will
be obtained from an antecubital vein. Approximately 10 ml of whole blood will
be obtained at each blood draw, and centrifuged at 7000 rpm to remove the serum
portion of the blood. Serum will be stored in a -80oC freezer for later analysis.
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Skeletal Muscle Function - Peak muscle force and fatigability will be assessed
following a standardized treadmill warm-up (3.5 mph; 5 min). See above for
details.



Resistance Exercise (RE) – The RE will consist of 100 unilateral knee extensions
performed at a fast speed (180 degrees per second) and 100 unilateral knee
extensions performed at a slow speed (30 degrees per second). The knee
extensions will be performed in sets of 10 (10 repetitions performed within each
set) with a 60 second rest in between sets. Subjects will be split into two groups
and randomly selected to perform the resistance exercise first with either their
dominant or non-dominant leg. The RE protocol is in line with previous literature
(1,2,6).

Follow-Up Visits (n=8; 30 min each):


Muscle Soreness - Soreness ratings will be obtained using a 100mm visual analog
scale, with 0 indicating no muscle soreness and 100 indicating impaired
movement due to muscle soreness.



Blood Sample – Fasting venous blood samples will be obtained from an
antecubital vein.



Skeletal Muscle Function - Peak muscle force and fatigability will be assessed
following a standardized treadmill warm-up (3.5 mph; 5 min). See above for
details.

Study Treatments
As outlined above, for each subject, one leg will be assigned to Placebo whereas the
opposite leg will be assigned to Ibuprofen. Subjects will ingest their respective treatment
capsules with water 3 x daily for 3 d, starting ~45 min prior to the initial RE test (upon
arrival in the laboratory), and in subsequent 6 hour time increments for the next 72 hours.
The subjects will send a photo or text to the investigators immediately upon consumption
of each capsule taken outside of the laboratory as evidence of consumption.



Placebo: Maltodextrin-filled capsules (carbohydrate)
Ibuprofen: The maximum daily over the counter dosage of Ibuprofen
(2400mg/day) concealed in capsules matching placebo

Dietary and Exercise Controls
Subjects will be asked to keep a dietary log (see Attachment C) beginning 24 hours prior
to the first RE session and for the next three days following the trial (4 days total). Upon
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returning in 72 hours for a follow-up visit, subjects will submit their initial diet records
and be provided with a copy to use as a template to replicate their diet for the same four
days surrounding each of the next 3 RE sessions.
Subjects will consume their final ‘self-selected’ meal no less than 12 hours prior to the
RE sessions and follow-up visits (i.e. dinner on the evening prior to testing). Subjects
will also be provided with a 500 kilocalories of Ensure Active following each RE
sessions (4 feedings). Subjects will be instructed to consume the feeding 60 min of RE
trial completion and then to refrain from any food or beverage intake until 4 hours
following RE trial completion.
Subjects will also be instructed to abstain from alcohol and caffeine for 24 and 12 hours,
respectively, prior to each RE trial and follow-up visit.
Subjects will be instructed to refrain from heavy exercise for 72 hours prior to the RE
trials as well as the 72 hours following each RE trial. Subjects will record all physical
activity performed throughout the duration of the study, beginning with 72 hours prior to
the initial RE trial (40 d) (see Attachment D). Subjects will also be instructed to abstain
from the use of any supplements to enhance recovery throughout the duration of the
study.
Dependent Measurements
All dependent measures will be assessed immediately prior to each RE trial and again 24
hours and 72 hours following each RE trial.


Skeletal Muscle Function - Peak isokinetic concentric muscle force and
fatigability will be assessed with BioDex. See above for details.



Muscle Soreness - Soreness ratings will be obtained using a 100mm visual analog
scale will be obtained immediately following ascending, and descending a flight
of stairs at normal walking speed.



Biomarkers – Blood samples will be analyzed for serum biomarkers of
inflammation [(Interleukin-6 (IL-6) and TNF-alpha (TNF-a)] and muscle
membrane disruption [creatine kinase (CK) and Brain Derived Neurotropic Factor
(BDNF)]

Risks
Blood Sampling
The risks of blood sampling using venipuncture include possible mild bruising, and the
risk of transfer of blood-borne pathogens, as well as possible risks of infection or skin
irritation. These risks are considered to be minimal, and all safety precautions for handing
blood samples will be followed according to OSHA protocols, including: investigators
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will wear latex gloves at all times during blood sampling and testing. A sharps container
lined with a biohazard bag will be used for all sharp objects involved in the blood
sampling; all other materials (i.e. gloves, gauze pads, etc.) used during the sampling will
be put in a separate waste disposal unit lined with a biohazard bag. Both investigators
who will be involved in blood draws (and handling of blood) have been trained in these
phlebotomy techniques, and completed JMU blood-borne pathogen training. The total
amount of blood obtained during this study is approximately 120 ml. For reference, this
amount is ~ 1/3 of a can of soda, or 25% of the amount given when donating blood in a
single session (approximately 1 pint, or 473 ml). This amount of blood is the minimum
required to perform the assays for CK, BDNF, IL-6 and TNF-α and to assess the timecourse changes in these variables as a result of the exercise sessions. Subjects will be
instructed to refrain from donating blood during the study period.
Skeletal Muscle Function
The risks of BioDex muscle function testing include soreness from exertion 24-48 hours
post and potential lightheadedness or loss of consciousness if correct form is not utilized.
Participants will be instructed in correct form and breathing techniques prior to testing.
VO2max test and Resistance Exercise Trials
According to the American College of Sports Medicine’s Guidelines for Exercise Testing
and Prescription, the risk associated with heavy exercise for individuals categorized as
“low risk” is very minimal, and physician supervision is not necessary. The conditions
that the exercise sessions are to take place are likely safer than the typical exercise
environments of the subjects. Any subjects who do not meet the ACSM criteria for “low
risk” will not be allowed to participate in the study. In the unlikely event of cardiac or
other complications during exercise, an emergency plan is in place. This includes
immediate access to a phone to call emergency personnel. In addition, at least one of the
listed investigators will be present during the exercise sessions, and both are CPR
certified.
The resistance exercise trials will likely evoke a large amount of muscle soreness that
may persist for up to 7 d following exercise. The amount of soreness is similar to that
experienced following unaccustomed vigorous physical activity (e.g. descending on a
hike, playing a game of basketball, football, ultimate Frisbee, etc.)
Ibuprofen
The use of Ibuprofen may be associated with an increased risk of gastrointestinal (GI)
events such as bleeding, ulcers within the stomach, and heart attack. However, serious GI
reactions and CV risks are extremely low given the 3-day dosing regimen in this study.
These events are more likely to occur if you have a history of ulcers, partake in drinking
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and smoking regularly, are over the age of 60, are on blood thinners or blood pressure
medication. Other possible side effects include rash, flare of asthma, temporary vision
changes, dizziness, abdominal pain, upset stomach, burping, bloating, cloudy urine,
diarrhea, decrease in urine production, constipation, heartburn, indigestion, and shortness
of breath (8). Another possible risk is drug interaction with other medications such as
increased bleeding risk if taken with anticoagulants, increased serum lithium levels,
increased toxicity of methotrexate, or decreased effectiveness of diuretics. The research
participants will be strongly encouraged to communicate any suspected or observed side
effects (whether it is listed above or not) of the treatments with one of the investigators or
Dr. Diduch.
Benefits
All participants will gain valuable knowledge about their own muscular physiology and
information regarding the potential influence of Ibuprofen on adaptations to
unaccustomed exercise. Subjects will also receive a free VO2max test (valued at ~$150)
and subjects that complete all phases of data collection will be entered into 3 random
drawings for $125.
Data Analysis
This study will utilize a counterbalanced, between-subject design to examine the effects
of Ibuprofen on prophylactic adaptations to exercise, compared to placebo. Dependent
measurements will be examined with (treatment x time) ANOVAs. It is hypothesized that
Ibuprofen will interfere with prophylactic adaptations to exercise, thus leading to larger
amounts of muscle soreness, membrane disruption, and decrements in muscle function
following the second treadmill session, compared to placebo. Statistical significance will
be set at p ≤ 0.05 for these analyses.
Data Handling
Participation in this research will not be completely anonymous due to the inevitable
familiarity of the research team with some of the subjects. However, all subjects will be
assigned an individual identification number to ensure that the data remains confidential.
All files will be coded with the identification number. Coding sheets with participants'
names and corresponding identification numbers along with consent forms will be kept,
indefinitely, in a locked filing cabinet by Dr. Luden separate from the data files. All hard
copies of data (coded with ID number) will be stored, indefinitely, separately in locked
file cabinets in the Human Performance Lab. Electronic data and files will be stored,
indefinitely, on a password-protected computer, and will only contain de-identified
information. Only the identification number will be entered into the computer when
creating data spreadsheets and therefore subject’s names will not be available to those
analyzing and interpreting the data.
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Reporting Procedures
The results from this study may be presented at physiological conferences and in
professional journals.
Participants will not be identified in reports, and data from
individual subjects will not be reported in a manner that would render it possible for
participants to be identified. Target audiences for these results include, but are not
limited to, JMU faculty, peer review professional journals, and physiology conference
participants. In addition, the final aggregate results of the study will be made available to
each of the subjects upon request.
Vulnerable Population
Data will not be gathered on minors, prisoners, pregnant women, fetusus, neonates,
cognitively impaired persons, or other protected or potentially vulnerable populations.
Deception
No deception will be used.
Experience of the Researchers
Nicholas D. Luden, Ph.D. is an Assistant Professor of Exercise Physiology and Interim
Director of JMU’s Human Performance Laboratory. He has published >15 peerreviewed manuscripts in the field of exercise physiology. His primary research interests
revolve around skeletal muscle function and how it can be optimized using training
and/or nutritional strategies. He has accumulated a substantial amount of both basic and
applied laboratory experience over the past decade, the majority of which has been
gained while conducting research on endurance athletes.
Jessica G. Ehrbar is a first-year graduate student in Exercise Physiology and a recent
graduate of our undergraduate Kinesiology program. Over the past couple years, she has
gained significant research experience through volunteer and practicum hours performed
in our laboratory.

62

References
1. Crameri RM, Aagaard P, Qvortrup K, Langberg H, Olesen J, Kjaer M. Myofibre
damage in human skeletal muscle: Effects of electrical stimulation versus voluntary
contraction. J Physiol. 2007 Aug 15;583(Pt 1):365-80.
2. Crameri RM, Langberg H, Magnusson P, Jensen CH, Schroder HD, Olesen JL, et al.
Changes in satellite cells in human skeletal muscle after a single bout of high intensity
exercise. J Physiol. 2004 Jul 1;558(Pt 1):333-40.
3. Green GA. Understanding NSAIDs: From aspirin to COX-2. Clin Cornerstone.
2001;3(5):50-9.
4. Hasson SM, Daniels JC, Divine JG, Niebuhr BR, Richmond S, Stein PG, et al. Effect
of ibuprofen use on muscle soreness, damage, and performance: A preliminary
investigation. Med Sci Sports Exerc. 1993 Jan;25(1):9-17.
5. Mackey AL, Kjaer M, Dandanell S, Mikkelsen KH, Holm L, Dossing S, et al. The
influence of anti-inflammatory medication on exercise-induced myogenic precursor cell
responses in humans. J Appl Physiol (1985). 2007 Aug;103(2):425-31.
6. Mikkelsen, U. R., Langberg, H., Helmark, I. C., Skovgaard, D., Andersen, L. L., Kjaer,
M., & Mackey, A. L. (2009). Local NSAID infusion inhibits satellite cell proliferation in
human skeletal muscle after eccentric exercise. Journal of applied physiology, 107(5),
1600-1611
7. Paulsen G, Egner I, Drange M, Langberg H, Benestad H, Fjeld J, et al. A COX‐2
inhibitor reduces muscle soreness, but does not influence recovery and adaptation after
eccentric exercise. Scand J Med Sci Sports. 2010;20(1):e195-207.
8. Rainsford K. Ibuprofen: Pharmacology, efficacy and safety. Inflammopharmacology.
2009;17(6):275-342.
9. Trappe TA, White F, Lambert CP, Cesar D, Hellerstein M, Evans WJ. Effect of
ibuprofen and acetaminophen on postexercise muscle protein synthesis. Am J Physiol
Endocrinol Metab. 2002 Mar;282(3):E551-6.

63

Attachment A
James Madison University
Department of Kinesiology
Informed Consent
Purpose
I, ________________________, hereby agree on _______________ (date) to participate
in the research project conducted by Dr. Nick Luden and Jessica Ehrbar from James
Madison University titled “The Effects of Ibuprofen on Prophylactic Adaptations to
Heavy Exercise”
The primary goal of this study is to examine if Ibuprofen use affects muscle adaptations
to heavy resistance exercise.
Subject Responsibility
I understand that I will undergo the following testing in the study:
You will be asked to visit the Human Performance Laboratory (Godwin 209) a total of 16
times and the James Madison University Health Center to see Dr. Diduch for a health
screening. Specifically, you will be asked to report to the James Madison University
Health Center to be health screened prior to participation and to receive a prescription for
the Ibuprofen and placebo treatments to be filled at the James Madison University Health
Center Pharmacy (at no cost). Also, you will report to the laboratory for one preliminary
trial, three familiarization trials, four experimental trials, and eight follow up visits 24 and
72 hours after the experimental trials. The preliminary tests will require approximately 60
minutes, familiarization trials will require approximately 15 minutes, experimental trials
will require approximately 60 minutes, and the eight follow up trials will require
approximately 30 minutes, for a total time commitment of approximately 11 hours in
addition to completing dietary and physical activity records. Detailed information for
each of these trials is provided below:
Preliminary Testing
Before any physical evaluation is given, you will be asked to complete screening forms
and an informed consent, to ensure that you meet the study criteria, that you do not have
any risk factors for heavy exercise, and that you do not have any known allergies to any
non-steroidal anti-inflammatory drugs. In the process of filling out these forms, you will
be asked to share information regarding your general health and lifestyle with the
researchers. If you meet the criteria for the study, the researchers will measure your
height and weight and you will perform a cardiorespiratory fitness test. During this
assessment, an exercise test will be conducted to determine your maximal oxygen uptake
(VO2max). To do this, you will ride a stationary cycle at an initial workload that is ‘fairly
easy’. Workload will be increased by 25 watts every 2 minutes during the test. You
will be encouraged to continue to cycle until you request to stop due to fatigue or are
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unable to continue at a cadence >50 revolutions per minute. After the VO2max test, a test
measuring muscle function will be performed. This test will be conducted using a Biodex
muscle function device (Biodex Medical Systems Inc., Shirley NY). Peak unilateral
isokinetic force (power) and fatigability will be assessed by having you push as hard as
possible against a shin pad that is connected to an electronic device that controls speed of
movement through the leg-extension. You will perform a trial comprised of 10
continuous leg-extension repetitions. The purpose of this session is to familiarize you
with the equipment and procedures to minimize learning and improve reliability during
the experimental trials.

Familiarization Trials
You will then be asked to return several days following the initial pre-testing to perform
another Biodex familiarization session. Two additional familiarization Biodex sessions
will be performed by your opposite leg prior to the second phase of the study.
Experimental Trials
Following preliminary/familiarization testing, you will be asked to perform four total
trials of unilateral knee extensions (two trials for each leg). The two trials performed with
the same leg will be separated by 10 days and the two sets of trials will be separated by 7
days.
Resistance Exercise: The RE will consist of 100 one-legged knee extensions performed at
a fast speed (180 degrees per second) and 100 one-legged knee extensions performed at a
slow speed (30 degrees per second). The knee extensions will be performed in sets of 10
(10 repetitions performed within each set) with a 60 second rest in between sets.
Muscle Soreness: You will evaluate your muscle soreness using a visual scale with 0
indicating (i.e.) no muscle soreness and 100 indicating impaired movement due to muscle
soreness. This will be done before each of the experimental trials.
Blood Sample: Following 5 minutes of rest, blood samples will be obtained.
Approximately 10 ml of whole blood will be obtained at each blood draw. This will be
performed before each RE trial.
Muscle Function Test (Biodex Isokinetic Dynamometer): Following a 5-minute treadmill
warm-up (walking), you will be asked to perform 30 maximal one-legged leg extensions.
Follow-Up Visits
You will be asked to return to the lab 24 and 72 hours following each resistance exercise
trial for muscle function and soreness testing, and blood sampling.
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Muscle Soreness: You will evaluate your muscle soreness using a visual scale with 0
indicating (i.e.) no muscle soreness and 100 indicating impaired movement due to muscle
soreness. This will be done before each of the experimental trials.
Blood Sample: Following 5 minutes of rest, blood samples will be obtained.
Approximately 10 ml of whole blood will be obtained at each blood draw. This will be
performed before each RE trial.
Muscle Function Test (Biodex Isokinetic Dynamometer): Following a 5-minute treadmill
warm-up (walking), you will be asked to perform 30 maximal one-legged leg extensions.

Study Treatments
Approximately 45 minutes before entering the lab for the resistance exercise trial, you
will be required to consume 800mg of either Ibuprofen or Placebo. Every six hours for
the next 72 hours, 800mg of Ibuprofen will be ingested, for a total of 9 doses of Placebo
and 9 doses of Ibuprofen over the course of the study. You will be required to send a text
or picture for verification to the researcher immediately following each dose.

Dietary, Exercise, and Medication Controls
You will be asked to complete a diet record for 4 days beginning 24 hours prior to the
initial treadmill trial. You will submit your initial diet records the morning of your first
72 hours follow-up trial (diet records from previous 4 days). A copy of your initial
dietary records will then be provided, which you will be asked to use as a template when
replicating your dietary habits during the 4 days around the second treadmill trial (24
hours prior and 72 hours after).
You will consume a final ‘self-selected’ meal no less than 12 hours prior to the start of
RE trials and follow-up visits (i.e. dinner on the evening prior to testing). You will also
be provided with a 500 kilocalories of Ensure Active following each RE sessions (4
feedings). You will be instructed to consume the feeding 60 minutes of RE trial
completion and then to refrain from any food or beverage intake until 4 hours following
RE trial completion..
You will also be instructed to abstain from alcohol and caffeine for 24 and 12 hours,
respectively, prior to each resistance exercise (RE) trial and follow-up visit.
You will be instructed to refrain from heavy exercise for 72 hours prior to the RE trials as
well as the 72 hours following each RE trial. All physical activity performed throughout
the duration of the study will be recorded, beginning with 72 hours prior to the initial
treadmill trial (40 days). You will also be instructed to abstain from the use of any
supplements to enhance recovery throughout the duration of the study.
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You will be instructed to refrain from consumption of other nonsteroidal drugs (e.g.
ibuprofen, advil, motrin, aleve, naproxen) starting 4 days prior to the initial trial and for
the duration of the project.

Risks:
VO2max test and Resistance Exercise Trials
You are expected to be honest about disclosing all known risk factors to the researcher.
According to the American College of Sports Medicine, the risks associated with
maximal exercise/testing for healthy individuals are very minimal. If you do not meet
the criteria for “low risk”, you will not be allowed to participate in the study. In the
unlikely event of cardiac or other complications during exercise, an emergency plan is in
place. This includes immediate access to a phone to call emergency personnel. In
addition, each of the investigators is CPR certified.
The resistance exercise will likely evoke a large amount of muscle soreness that may
persist for up to 7 days following exercise. The amount of soreness is similar to that
experienced following unaccustomed vigorous physical activity (e.g. descending on a
hike, playing a game of basketball, football, ultimate Frisbee, etc.) The degree of soreness
may very between individuals based upon their responses to muscle damage and
recovery.
Blood Sampling
The risks of blood sampling using venipuncture include possible mild bruising, and the
risk of transfer of blood-borne pathogens, as well as possible risks of infection or skin
irritation. These risks are considered to be minimal, and all safety precautions for handing
blood samples will be followed according to OSHA protocols, including: investigators
will wear latex gloves at all times during blood sampling and testing. A sharps container
lined with a biohazard bag will be used for all sharp objects involved in the blood
sampling; all other materials (i.e. gloves, gauze pads, etc.) used during the sampling will
be put in a separate waste disposal unit lined with a biohazard bag. All trash bags will be
taken to Rockingham Memorial Hospital for disposal. Both investigators who will be
involved in blood draws (and handling of blood) have been trained in these phlebotomy
techniques, and completed JMU blood-borne pathogen training. The total amount of
blood obtained during this study is approximately 120 ml. For reference, this amount is ~
1/3 of a can of soda, or 25% of the amount given when donating blood in a single session
(approximately 1 pint, or 473 ml). This amount of blood is the minimum required to
perform the assays for CK, BDNF, IL-6 and TNF-α and to assess the time-course
changes in these variables as a result of the exercise sessions. Subjects will be instructed
to refrain from donating blood during the study period.
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Skeletal Muscle Function
The risks of BioDex muscle function testing include soreness from exertion 24-48 hours
post and potential lightheadedness or loss of consciousness if correct form is not utilized.
Participants will be instructed in correct form and breathing techniques prior to testing.
Ibuprofen Use
The use of Ibuprofen may be associated with an increased risk of gastrointestinal (GI)
events such as bleeding, ulcers within the stomach, and heart attack. However, serious GI
reactions and CV risks are extremely low given the 3-day dosing regimen in this study.
These events are more likely to occur if you have a history of ulcers, partake in drinking
and smoking regularly, are over the age of 60, are on blood thinners or blood pressure
medication. Other possible side effects include rash, flare of asthma, temporary vision
changes, dizziness, abdominal pain, upset stomach, burping, bloating, cloudy urine,
diarrhea, decrease in urine production, constipation, heartburn, indigestion, and shortness
of breath (8). Another possible risk is drug interaction with other medications such as
increased bleeding risk if taken with anticoagulants, increased serum lithium levels,
increased toxicity of methotrexate, or decreased effectiveness of diuretics. You are
strongly encouraged to communicate any suspected or observed side effects (whether it is
listed above or not) of the treatments with one of the investigators or Dr. Diduch.
Benefits
You will gain valuable knowledge about your own muscular physiology and information
regarding the potential influence of Ibuprofen on adaptations to unaccustomed exercise.
You will also receive a free VO2max test (valued at ~$150) and will be entered into 3
random drawings for $125, if all phases of data collection are completed.
Inquiries
You may have questions or concerns during the time of your participation in this study,
or after its completion. If you have any questions about the study, contact Nicholas D.
Luden, Ph.D. at ludennd@jmu.edu or by phone at 540-568-4068.

Questions about Your Rights as a Research Subject
Dr. David Cockley
Chair, Institutional Review Board
James Madison University
(540) 568-2834
cocklede@jmu.edu

Confidentiality
All data and results will be kept confidential. You will be assigned an identification
code. At no time will your name be identified with your individual data. The researcher
retains the right to use and publish non-identifiable data. All data will be kept secured in
a locked cabinet. Final aggregate results will be made available to you upon request.
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Freedom of Consent
Your participation is entirely voluntary. You are free to choose not to participate.
Should you choose to participate, you can withdraw at any time without consequences of
any kind.
I have read this consent form and I understand what is being requested of me as a
participant in this study. I freely consent to participate. I have been given satisfactory
answers to my questions. The investigator provided me with a copy of this form. I
certify that I am at least 18 years of age.

Name of Subject (Printed)

Name of Researcher (Printed)

Name of Subject (Signed)

Name of Researcher (Signed)

Date

Date
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Attachment B
AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire
Assess your health status by marking all true statements
History
You have had:
If you marked any of these
a heart attack
statements in this section, consult
heart surgery
your physician or other appropriate
cardiac catheterization
health care provider before engaging
coronary angioplasty (PTCA)
in exercise. You may need to use a
pacemaker/implantable cardiac
facility with a medically qualified
defibrillator/rhythm disturbance
staff.
heart valve disease
heart failure
heart transplantation
congenital heart disease
Symptoms
You experience chest discomfort with exertion
You experience unreasonable breathlessness
You experience dizziness, fainting, or blackouts
You take heart medications
Other Health Issues
You have diabetes
You have asthma or other lung disease
You have burning or cramping sensation in your lower
legs when walking short distances
You have musculoskeletal problems that limit your
physical activity
You have concerns about the safety of exercise
You take prescription medication(s)

Cardiovascular risk factors
You are a man older than 45 years
You smoke, or quit smoking within the previous 6 mo.
Your blood pressure is > 140/90 mmHg
You do not know your blood pressure
You take blood pressure medication
Your blood cholesterol level is > 200 mg/dl
You do not know your cholesterol level
You have a close blood relative who had a heart attack or
heart surgery before age 55 (father or brother) or age 65
(mother or sister)
You are physically inactive (i.e. you get < 30 minutes of

If you marked two or more of the
statements in this section, you
should consult your physician or
other appropriate health care
provider before engaging in
exercise. You might benefit from
using a facility with a
professionally qualified exercise
staff to guide your exercise
program.
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physical activity on at least 3 days of the week)
You are > 20 pounds overweight

None of the above
You should be able to exercise safely
without consulting your physician or
other appropriate health care
provider in a self-guided program or
almost any facility that meets your
exercise program needs.
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Attachment C
24-HOUR DIET RECORD
Subject number____________
Time

Date______________Day of Week______________
Food and/or Drink

Method of Preparation

Quantity Consumed

Adapted From: Lee RD, Nieman DC. Nutritional Assessment. 2nd ed. United States of America: Mosby; 1996.

Brand Name
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Attachment D
40-Day Physical Activity Records
Subject #

Date

Trial #
Type of Exercise
Performed

Duration of
Exercise (minutes)

Date:
Intensity of
Exercise
(use scale below)
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Intensity Scale
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Very, very light
Very light
Fairly light
Somewhat hard
Hard
Very hard
Very, very hard

74

Attachment E
Subject Prescreening Information
Please Complete the Following:
Age:

years

Height

Weight

Blood Pressure _______________

Typical Exercise Habits over the Past 3 Months:
Average number of days of exercise per week
Average number of hours of exercise per week
Type of Exercise_______________________

Do you have a muscle or joint injury/condition that precludes the completion of
the strenuous unilateral leg extension protocol? If yes, please explain.

Are you allergic to Aspirin or any Non-Steroidal Anti-Inflammatory Drugs
(NSAIDs) such as Ibuprofen, Motrin, Advil, etc.,? Have you taken any within
the past 7 days?

Are you currently taking any prescription, or OTC medicine? If yes, please list
medications.

Name of Subject (Printed)

B. Kent Diduch, M.D. (Printed)

Name of Subject (Signed)

B. Kent Diduch, M.D. (Signed)

Date

Date
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